[go: up one dir, main page]

CR10499A - Profarmaco de compuesto de cinamida - Google Patents

Profarmaco de compuesto de cinamida

Info

Publication number
CR10499A
CR10499A CR10499A CR10499A CR10499A CR 10499 A CR10499 A CR 10499A CR 10499 A CR10499 A CR 10499A CR 10499 A CR10499 A CR 10499A CR 10499 A CR10499 A CR 10499A
Authority
CR
Costa Rica
Prior art keywords
profarmaco
formula
cinamide
compound
cinamide compound
Prior art date
Application number
CR10499A
Other languages
English (en)
Inventor
Teiji Kimura
Koki Kawano
Noritaka Kitazawa
Nobuaki Sato
Toshihiko Kaneko
Koichi Ito
Mamoru Takaishi
Ikuo Kushida
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of CR10499A publication Critical patent/CR10499A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Cultivation Of Plants (AREA)
  • Seasonings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La descripcion es un profarmaco optimo de un compuesto de cinamida representado por la formula (I) a continuacion en la formula, Ra y Rb respectivamente representan un grupo alquilo C1-6 o los similares; Xa representa un grupo metoxi o un atomo de fluor; y representa un grupo fosfono o los similares; y A representa un derivado de lactama ciclico.
CR10499A 2006-07-28 2008-12-11 Profarmaco de compuesto de cinamida CR10499A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82076106P 2006-07-28 2006-07-28
JP2006206007 2006-07-28
US86925906P 2006-12-08 2006-12-08
JP2006331274 2006-12-08

Publications (1)

Publication Number Publication Date
CR10499A true CR10499A (es) 2009-03-20

Family

ID=38981524

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10499A CR10499A (es) 2006-07-28 2008-12-11 Profarmaco de compuesto de cinamida

Country Status (25)

Country Link
US (1) US7737141B2 (es)
EP (1) EP2048143A4 (es)
JP (1) JPWO2008013213A1 (es)
KR (1) KR20090033910A (es)
AR (1) AR062095A1 (es)
AU (1) AU2007277729A1 (es)
CA (1) CA2658037A1 (es)
CO (1) CO6150153A2 (es)
CR (1) CR10499A (es)
EA (1) EA200970172A1 (es)
EC (1) ECSP099091A (es)
GE (1) GEP20115176B (es)
HN (1) HN2009000157A (es)
IL (1) IL196351A0 (es)
MA (1) MA30636B1 (es)
MX (1) MX2008015504A (es)
MY (1) MY144971A (es)
NO (1) NO20090541L (es)
NZ (1) NZ574102A (es)
PE (1) PE20080281A1 (es)
SA (1) SA07280403B1 (es)
SV (1) SV2009003157A (es)
TN (1) TN2009000024A1 (es)
TW (1) TW200821319A (es)
WO (1) WO2008013213A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1757591A4 (en) * 2004-05-26 2010-05-05 Eisai R&D Man Co Ltd ZIMTSÄUREAMIDVERBINDUNG
ATE458729T1 (de) * 2004-10-26 2010-03-15 Eisai R&D Man Co Ltd Amorphe form einer zimtsäureamidverbindung
EP1953151A4 (en) * 2005-11-18 2010-06-02 Eisai R&D Man Co Ltd SALTS FROM A CYNNAMIDE COMPOUND OR SOLVATE THEREOF
KR20080076907A (ko) * 2005-11-18 2008-08-20 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 유도체의 제조 방법
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
AU2006317457B2 (en) * 2005-11-24 2011-09-08 Eisai R & D Management Co., Ltd. Morpholine type cinnamide compound
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
AR062095A1 (es) 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
TW200848054A (en) * 2007-02-28 2008-12-16 Eisai R&D Man Co Ltd Two cyclic oxomorpholine derivatives
CA2687262A1 (en) * 2007-05-16 2008-11-20 Naoyuki Shimomura One-pot production process for cinnamide derivative
EP2559693B1 (en) 2007-08-31 2014-11-26 Eisai R&D Management Co., Ltd. Polycyclic compound
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
RU2527177C2 (ru) 2007-12-20 2014-08-27 Энвиво Фармасьютикалз, Инк. Четырехзамещенные бензолы
EP2234999A1 (en) 2007-12-21 2010-10-06 F. Hoffmann-La Roche AG Heteroaryl derivatives as orexin receptor antagonists
ATE535515T1 (de) 2008-01-11 2011-12-15 Hoffmann La Roche Modulatoren für amyloid beta
WO2009096349A1 (ja) * 2008-01-28 2009-08-06 Eisai R & D Management Co., Ltd. 結晶性のシンナミド化合物またはその塩
JP5328816B2 (ja) 2008-02-22 2013-10-30 エフ．ホフマン−ラ ロシュ アーゲー アミロイドβの調節薬
JP5502089B2 (ja) 2008-10-09 2014-05-28 エフ．ホフマン−ラ ロシュ アーゲー アミロイドβのモジュレーター
CA2743196A1 (en) 2008-11-10 2010-05-14 F.Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
ES2711619T3 (es) * 2010-07-02 2019-05-06 Bio Pharm Solutions Co Ltd Compuesto carbamato de fenilo y relajante muscular que contiene dicho compuesto
KR101551041B1 (ko) 2011-01-13 2015-09-07 (주)바이오팜솔루션즈 페닐 카바메이트 유도체의 제조방법
US8901066B2 (en) 2011-06-15 2014-12-02 Basf Se Branched polyesters with sulfonate groups
BR112013031119A2 (pt) 2011-06-15 2016-12-06 Basf Se poliéster ramificado, mistura, uso dos poliésteres ramificados, e, método para produzir poliésteres ramificados
MX338554B (es) 2011-12-27 2016-04-20 Bio Pharm Solutions Co Ltd Compuestos de fenil carbamato para usarse en aliviar o tratar el dolor.
ES2998534T3 (en) 2013-03-12 2025-02-20 Bio Pharm Solutions Co Ltd Phenyl carbamate compounds for use in preventing or treating pediatric epilesy
EP2970112A4 (en) * 2013-03-12 2017-01-04 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for preventing or treating a memory loss-related disease comprising the same
PL3552017T3 (pl) 2016-12-09 2022-08-08 Denali Therapeutics Inc. Związki użyteczne jako inhibitory RIPK1
CN110143935B (zh) * 2019-06-03 2022-09-30 华侨大学 一种2，5-二取代呋喃衍生物的制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0219756B1 (de) 1985-10-09 1994-01-05 Shell Internationale Researchmaatschappij B.V. Neue Acrylsäureamide
DE3541716A1 (de) 1985-11-26 1987-05-27 Celamerck Gmbh & Co Kg Neue acrylsaeureamide
JPH03206042A (ja) 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
DK0468054T3 (da) * 1990-02-08 1997-06-16 Eisai Co Ltd Benzensulfonamidderivat
JPH05194517A (ja) 1992-01-16 1993-08-03 Tanabe Seiyaku Co Ltd ６−メルカプトプリン誘導体及びその製法
AU680870B2 (en) 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
EP0784612A1 (en) 1994-10-04 1997-07-23 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
JPH08283219A (ja) 1995-04-07 1996-10-29 Eisai Co Ltd アラルキルアミノアルキルアミド誘導体
EE9800390A (et) 1996-05-10 1999-06-15 Icos Corporation Karboliini derivaadid
AU740263C (en) 1996-07-22 2002-05-16 Monsanto Company Thiol sulfonamide metalloprotease inhibitors
JP2001508767A (ja) 1996-12-02 2001-07-03 藤沢薬品工業株式会社 ５―ｈｔ拮抗作用を有するインドール―ウレア誘導体
CA2281875A1 (en) 1997-03-31 1998-10-08 Takeda Chemical Industries, Ltd. Azole compounds, their production and their use
JP3108997B2 (ja) 1997-03-31 2000-11-13 武田薬品工業株式会社 アゾール化合物、その製造法および用途
AU754965B2 (en) * 1997-12-31 2002-11-28 University Of Kansas, The Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
GB9816984D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US6235728B1 (en) * 1999-02-19 2001-05-22 Bristol-Myers Squibb Company Water-soluble prodrugs of azole compounds
PL349781A1 (en) 1999-02-26 2002-09-09 Merck & Co Inc Novel sulfonamide compounds and uses thereof
US7053087B1 (en) * 1999-03-04 2006-05-30 Cardiome Pharma Corp. Aminocycloalkyl cinnamide compounds for arrhythmia and analgesics and anesthetics
US20040087798A1 (en) * 2000-03-14 2004-05-06 Akira Yamada Novel amide compounds
US20010051642A1 (en) * 2000-04-17 2001-12-13 Kyunghye Ahn Method for treating Alzheimer's disease
AU2001254555A1 (en) 2000-04-24 2001-11-07 Merck Frosst Canada & Co Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore
DK1349839T3 (da) * 2000-12-04 2005-06-06 Hoffmann La Roche Phenylethenyl- eller phenylethinylderivater som glutamatraceptorantagonister
GB0108770D0 (en) * 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
MXPA04005427A (es) 2001-12-10 2005-04-19 Amgen Inc Ligandos de receptor vainilloide y su uso en tratamientos.
BR0215182A (pt) 2001-12-20 2004-10-19 Bristol Myers Squibb Co Derivados de (alfa)- (n-sulfonamido) acetamida como inibidores de (beta)-amilóide
JP2003206280A (ja) 2001-12-28 2003-07-22 Takeda Chem Ind Ltd ビアリール化合物およびその用途
DE10211101A1 (de) 2002-03-14 2003-09-25 Basf Ag Katalysatoren und Verfahren zur Herstellung von Aminen
GB0207436D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
CA2486376A1 (en) * 2002-05-22 2003-12-04 Amgen Inc. Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
EP1511710B1 (en) 2002-05-31 2013-11-20 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer s disease, type 2 diabetes, and parkinson s disease
DE50312261D1 (de) 2002-07-12 2010-02-04 Sanofi Aventis Deutschland Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US6900354B2 (en) 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
JP2006518738A (ja) * 2003-02-12 2006-08-17 トランス　テック　ファーマ，インコーポレイテッド 治療薬としての置換アゾール誘導体
CN102584813B (zh) * 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
US8362017B2 (en) * 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
CA2551038C (en) 2003-12-22 2010-04-27 Pfizer Inc. Triazole derivatives as vasopressin antagonists
CN1922151A (zh) * 2004-02-12 2007-02-28 特兰斯泰克制药公司 取代的吡咯衍生物、组合物和使用方法
EP1757591A4 (en) 2004-05-26 2010-05-05 Eisai R&D Man Co Ltd ZIMTSÄUREAMIDVERBINDUNG
ATE458729T1 (de) 2004-10-26 2010-03-15 Eisai R&D Man Co Ltd Amorphe form einer zimtsäureamidverbindung
US20060241038A1 (en) 2005-04-20 2006-10-26 Eisai Co., Ltd. Therapeutic agent for Abeta related disorders
WO2007034282A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
KR20080076907A (ko) * 2005-11-18 2008-08-20 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 유도체의 제조 방법
EP1953151A4 (en) 2005-11-18 2010-06-02 Eisai R&D Man Co Ltd SALTS FROM A CYNNAMIDE COMPOUND OR SOLVATE THEREOF
US20070117839A1 (en) * 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
AU2006317457B2 (en) * 2005-11-24 2011-09-08 Eisai R & D Management Co., Ltd. Morpholine type cinnamide compound
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
CA2643796A1 (en) 2006-03-09 2007-09-13 Eisai R & D Management Co., Ltd. Polycyclic cinnamide derivatives
AR062095A1 (es) 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
EP2117311A4 (en) 2007-02-08 2011-05-11 Merck Sharp & Dohme Therapeutic agents
RU2009144998A (ru) 2007-05-07 2011-06-20 Шеринг Корпорейшн (US) Модуляторы гамма-секретазы
ATE496915T1 (de) * 2007-05-11 2011-02-15 Hoffmann La Roche Hetarylaniline als modulatoren für amyloid beta
EP2166854A4 (en) 2007-06-13 2012-05-16 Merck Sharp & Dohme TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS
PE20090957A1 (es) 2007-08-06 2009-07-13 Schering Corp Moduladores de gamma secretasa

Also Published As

Publication number Publication date
MX2008015504A (es) 2008-12-18
PE20080281A1 (es) 2008-05-05
WO2008013213A1 (en) 2008-01-31
TW200821319A (en) 2008-05-16
HN2009000157A (es) 2011-01-24
KR20090033910A (ko) 2009-04-06
SV2009003157A (es) 2010-01-12
NZ574102A (en) 2010-10-29
EA200970172A1 (ru) 2009-08-28
CO6150153A2 (es) 2010-04-20
US20090048213A1 (en) 2009-02-19
TN2009000024A1 (en) 2010-08-19
EP2048143A4 (en) 2010-11-03
US7737141B2 (en) 2010-06-15
CA2658037A1 (en) 2008-01-31
AU2007277729A1 (en) 2008-01-31
MY144971A (en) 2011-11-30
AR062095A1 (es) 2008-10-15
IL196351A0 (en) 2009-09-22
MA30636B1 (fr) 2009-08-03
NO20090541L (no) 2009-02-03
EP2048143A1 (en) 2009-04-15
JPWO2008013213A1 (ja) 2009-12-17
GEP20115176B (en) 2011-03-10
SA07280403B1 (ar) 2010-12-01
ECSP099091A (es) 2009-02-27

Similar Documents

Publication Publication Date Title
CR10499A (es) Profarmaco de compuesto de cinamida
CY1112705T1 (el) Συντηγμενες κυκλικες ενωσεις
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
CR8827A (es) Compuesto heterociclico fusionado
MA32956B1 (fr) Derives de 5-amino-2-(1-hydroxyethyl)-tetrahydropyrane
DK1954264T3 (da) Fremgangsmåde til fremstilling af epoxybutanol-mellemprodukter
RS53292B (en) CRYSTAL FORMS 2-THIAZOLYL-4-HINOLINYL-OXY DERIVATIVES, POWERFUL HCV INHIBITOR
RS54047B1 (en) PROCEDURE FOR OBTAINING 4-OXOCHINOLINE COMPOUNDS
HRP20120323T1 (en) Diarylhydantoin compounds
CR9830A (es) Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa
MA32731B1 (fr) Céphalosporine possédant un groupe catéchol
UY28290A1 (es) Compuestos farmacéuticos novedosos
EA201170096A1 (ru) Замещенные производные пиримидона
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
CR9369A (es) Compuestos de peridil acido acetico
RS53003B (en) C7-FLUORO SUBSTITUTED TETRACYCLINE UNITS
RS52632B (en) S-TRIAZOLYL ALFA-MERCAPTOACETANILIDE AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE
RS52900B (en) Benzoylpyrazole Compound, Process for Production and Production of Herbicides Containing Them
CY1113716T1 (el) Νεα μεθοδος συνθεσης της αγομελατινης
EA200802380A1 (ru) Совместные кристаллы пирролидинонов
EA200970372A1 (ru) Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
MY149400A (en) Bridged six-membered ring compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)